Evidence map›Paper›PMID 31455904›Full record

ArticleEye (London, England)2020

A new paradigm for delivering personalised care: integrating genetics with surgical interventions in BEST1 mutations.

Sancy Low, Ryian Mohamed, Alice Davidson, Maria Papadopoulos, Piergiacomo Grassi, Andrew R Webster, Graeme C Black, Paul J Foster, David F Garway-Heath, Philip A Bloom

Open access · bronzeAbstract read
In one paragraph

Article in Eye (London, England), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Stand-alone pars plana vitrectomy versus pars plana vitrectomy with retinopexy for retinal vasoproliferative tumors.Saudi journal of ophthalmology : official journal of the Saudi Ophthalmological Society
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Sancy LowMoorfields Eye Hospital NHS Foundation Trust, London, UK. sancy.low@ucl.ac.uk.ORCID http://orcid.org/0000-0001-8925-5971
Ryian MohamedDepartment of Ophthalmology, Central Middlesex Hospital, London, UK.ORCID http://orcid.org/0000-0001-8555-4659
Alice DavidsonUCL Institute of Ophthalmology, London, UK.
Maria PapadopoulosMoorfields Eye Hospital NHS Foundation Trust, London, UK.
Piergiacomo GrassiMoorfields Eye Hospital NHS Foundation Trust, London, UK.
Andrew R WebsterMoorfields Eye Hospital NHS Foundation Trust, London, UK.ORCID http://orcid.org/0000-0001-6915-9560
Graeme C BlackCentre for Genomic Medicine, Institute of Human Development, Faculty of Medical and Human Sciences, University of Manchester, Manchester, UK.ORCID http://orcid.org/0000-0001-8727-6592
Paul J FosterMoorfields Eye Hospital NHS Foundation Trust, London, UK.ORCID http://orcid.org/0000-0002-4755-177X
David F Garway-HeathMoorfields Eye Hospital NHS Foundation Trust, London, UK.ORCID http://orcid.org/0000-0003-2907-6992
Philip A BloomImperial College NHS Foundation Trust, London, UK.
Moorfields Eye Hospital NHS Foundation Trust · GBCentral Middlesex Hospital · GBUniversity of Manchester · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe availability and reduced cost of genotyping has improved gene susceptibility testing and our scientific understanding of disease pathophysiology. Whilst several personalised translational models exist within medical frameworks, genetic-based surgical therapy is a translational application not widely used in surgical specialties.

methodWe present a clinical series of five patients with genetically confirmed bestrophinopathy and malignant glaucoma (MG). Patients were followed up for 12 months or more after receiving surgical intervention to manage refractory intraocular pressure (IOP) resistant to medical treatment.

findingsPatients with BEST1 gene mutations are at higher risk of MG after filtration surgery. A multi-disciplinary approach after four patients experienced poor outcomes concluded that traditional first-line glaucoma surgery was not sufficient to prevent visual loss. A fifth patient presenting with the identified at-risk phenotype underwent primary pars plana vitrectomy, with pars plana Baerveldt tube insertion, successfully preventing MG and had no glaucoma progression after 5 years.

interpretationWe provide proof-of-principle that genetic analysis can be used to inform the selection of surgical therapy to improve outcomes. In this case, a refinement of current surgical methods to avoid MG. Although challenges remain, personalised surgery has the potential to improve clinical outcomes beyond the scope of current surgical practice.

Indexed as

GlaucomaGlaucoma Drainage ImplantsBestrophinsHumansIntraocular PressureMutationRetrospective StudiesTreatment OutcomeVitrectomyBEST1 protein, humanBestrophins

Identifiers

PMID31455904
PMCPMC7042240
OpenAlexW2971124238

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.